Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema (NAAVIGATE)

27 oktober 2026 bijgewerkt door: AbbVie

An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered Via Suprachoroidal Space (SCS) Injection Targeting Subjects With Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (CI-DME) (NAAVIGATE)

Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will assess surabgene lomparvovec (sura-vec) as a potential one-time gene therapy administered in the suprachoroidal space (SCS) for the treatment of diabetic retinopathy (DR) and prevention of vision-threatening events (VTEs) in participants with non-proliferative DR (NPDR) without center-involved diabetic macular edema (CI-DME).

This study will consist of 3 portions: a Phase 2b portion, a Phase 3 portion, and a bilateral treatment portion. Approximately 576 adult participants will be enrolled in the study across multiple sites in the United States and Puerto Rico.

In the Phase 2b and Phase 3 portions, participants will be randomized to different groups to receive sura-vec and prophylactic steroids or sham and artificial tears in their study eye. If assigned to sham, participants will be given an opportunity to cross over and receive treatment with sura-vec. In the bilateral treatment portion, participants will be enrolled to receive sura-vec and prophylactic steroids in both eyes. In all 3 portions, follow-up in the study will continue through 5 years following administration of sura-vec in each eye.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

576

Fase

  • Fase 2
  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Puerto Rico
      • Arecibo, Puerto Rico, 00612
        • Werving
        • Emanuelli Research & Development Center /ID# 275378
  • Verenigde Staten
    • Arizona
      • Mesa, Arizona, Verenigde Staten, 85206
        • Werving
        • Barnet Dulaney Perkins Eye Center - Mesa /ID# 283000
      • Phoenix, Arizona, Verenigde Staten, 85053
        • Werving
        • Retinal Consultants Of Arizona - Phoenix - North /ID# 283407
      • Scottsdale, Arizona, Verenigde Staten, 85255-4134
        • Werving
        • Retina Macula Institute of Arizona /ID# 282881
    • California
      • Bakersfield, California, Verenigde Staten, 93309
        • Werving
        • California Retina Consultants - Bakersfield /ID# 282990
      • Beverly Hills, California, Verenigde Staten, 90211
        • Werving
        • Retina-Vitreous Associates Medical Group - Beverly Hills /ID# 282995
      • Campbell, California, Verenigde Staten, 95008
        • Werving
        • Retinal Diagnostic Center /ID# 275055
      • Encino, California, Verenigde Staten, 91436
        • Werving
        • The Retina Partners /ID# 274741
      • Mountain View, California, Verenigde Staten, 94040-4119
        • Werving
        • Northern California Retina Vitreous Associates /ID# 282994
      • Pasadena, California, Verenigde Staten, 91107
        • Werving
        • California Eye Specialists Medical Group /ID# 274705
      • Poway, California, Verenigde Staten, 92064
        • Werving
        • Retina Consultants San Diego /ID# 274748
      • Sacramento, California, Verenigde Staten, 95841
        • Werving
        • Retinal Consultants - Sacramento - Greenback Lane /ID# 283018
      • San Francisco, California, Verenigde Staten, 94109
        • Werving
        • West Coast Retinal Medical Group /ID# 283007
      • Santa Barbara, California, Verenigde Staten, 93103
        • Werving
        • California Retina Consultants - Santa Barbara /ID# 283050
      • Torrance, California, Verenigde Staten, 90503
        • Werving
        • Macula Retina Vitreous Center - Torrance /ID# 282878
      • Walnut Creek, California, Verenigde Staten, 94598-5910
        • Werving
        • Bay Area Retina Associates /ID# 275032
    • Colorado
      • Durango, Colorado, Verenigde Staten, 81303
        • Werving
        • Southwest Retina Research Center /ID# 276094
      • Lakewood, Colorado, Verenigde Staten, 80228
        • Werving
        • Colorado Retina Associates /ID# 283006
      • Longmont, Colorado, Verenigde Staten, 80503
        • Werving
        • Advanced Vision Surgery Center /ID# 275017
    • Florida
      • Lakeland, Florida, Verenigde Staten, 33805
        • Werving
        • Florida Retina Consultants - Lakeland /ID# 275012
      • Orlando, Florida, Verenigde Staten, 32806
        • Werving
        • Florida Retina Institute - Orlando /ID# 283034
      • Pensacola, Florida, Verenigde Staten, 32503
        • Werving
        • Retina Speciality Institute /ID# 274996
    • Georgia
      • Augusta, Georgia, Verenigde Staten, 30909
        • Werving
        • Southeast Retina Center /ID# 274739
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60657
        • Werving
        • Illinois Retina Associates S.C /ID# 283048
      • Lemont, Illinois, Verenigde Staten, 60439
        • Werving
        • University Retina - Lemont /ID# 283021
      • Springfield, Illinois, Verenigde Staten, 62702
        • Werving
        • Springfield Clinic - First /ID# 283028
    • Kansas
      • Lenexa, Kansas, Verenigde Staten, 66215
        • Werving
        • Retina Associates - Lenexa /ID# 283004
    • Maine
      • Portland, Maine, Verenigde Staten, 04101
        • Werving
        • Maine Eye Center - Marginal Way Campus /ID# 275039
    • Maryland
      • Hagerstown, Maryland, Verenigde Staten, 21740
        • Werving
        • Mid Atlantic Retina Specialists - Hagerstown /ID# 274725
    • Nevada
      • Reno, Nevada, Verenigde Staten, 89502
        • Werving
        • Sierra Eye Associates /ID# 274737
    • New Jersey
      • Bloomfield, New Jersey, Verenigde Staten, 07003
        • Werving
        • Retina Center Of New Jersey /ID# 283088
    • Ohio
      • Middleburg Heights, Ohio, Verenigde Staten, 44130
        • Werving
        • Retina Associates Of Cleveland - Middleburg Heights Office /ID# 275985
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97221
        • Werving
        • Retina Northwest /ID# 283232
        • Contact:
          • Site Coordinator
          • Telefoonnummer: 215-662-8675
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29414
        • Werving
        • Charleston Neuroscience Institute - Charleston /ID# 275047
    • Texas
      • Austin, Texas, Verenigde Staten, 78705
        • Werving
        • Austin Research Center for Retina /ID# 276101
      • Bellaire, Texas, Verenigde Staten, 77401
        • Werving
        • Retina and Vitreous of Texas /ID# 283051
      • Burleson, Texas, Verenigde Staten, 76028
        • Werving
        • Star Retina /ID# 276513
      • Dallas, Texas, Verenigde Staten, 75231
        • Werving
        • Texas Retina Associates - Dallas /ID# 276117
    • Virginia
      • Norfolk, Virginia, Verenigde Staten, 23502
        • Werving
        • Wagner Macula & Retina Center - Norfolk /ID# 275021
      • Salem, Virginia, Verenigde Staten, 24153
        • Werving
        • Vistar Eye Center - Salem /ID# 282879

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Ocular (Study Eye for Phase 2b and Phase 3 Portions; Both Eyes for Bilateral Portion)

  • Moderately severe or severe nonproliferative diabetic retinopathy (NPDR) (early treatment diabetic retinopathy study-diabetic retinopathy severity scale [DRSS] level 47 or 53) for which panretinal photocoagulation (PRP) or anti- vascular endothelial growth factor (VEGF) can be safely deferred for at least 6 months after Screening Visit 1.
  • Best-corrected visual acuity (BCVA) in the study eye of >= 69 Early treatment diabetic retinopathy study letters (approximate Snellen equivalent 20/40 or better) at Screening Visit 1.

Systemic

• Diabetic retinopathy (DR) secondary to diabetes mellitus Type 1 or 2 with a hemoglobin A1c (HbA1c)< 12% within 60 days prior to Screening Visit 1.

Exclusion Criteria:

Ocular (Study Eye for Phase 2b and Phase 3 Portions; Both Eyes for Bilateral Portion)

  • Presence of active center involved-diabetic macular edema (CI-DME) in the study eye as determined by spectral domain optical coherence tomography (SD-OCT) evaluated by the central reading center (CRC), using the following threshold:

Central retinal thickness (CRT) >= 320 μm as measured by Heidelberg Spectralis SD-OCT (conversion to equivalent measurement is required and performed by the CRC if imaging is done with another SD-OCT instrument).

  • Active ocular inflammation including scleral inflammation (including episcleritis) or ocular/ periocular infection present in either eye at Screening Visit 1 or Screening Visit 2
  • Neovascularization from a cause other than DR, per investigator
  • Evidence or documented history of panretinal photocoagulation (PRP) or retinal laser therapy
  • History of intravitreal therapy, including anti-VEGF and long- or short-acting steroid therapy, within the prior 6 months and documentation of more than 10 prior anti-VEGF or short acting steroid intravitreal injections within 36 months of Screening Visit 1
  • Pregnant and breastfeeding individuals are excluded from this clinical study.

Systemic

  • Initiation of intensive insulin treatment (pump or multiple daily injections) within the past 6 months or plans to do so within 52 weeks after Day 1
  • Initiation of any treatment containing a GLP-1 receptor agonist within the 3 months prior to Screening Visit 1 or plans to do so within 52 weeks after Day 1
  • Pregnant and breastfeeding individuals are excluded from this clinical study

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Phase 2b: Surabgene Lomparvovec + Steroid-Regimen A

Participants will receive a single Suprachoroidal space (SCS) injection dose of surabgene lomparvovec (sura-vec) + steroid-Regimen A.
Geneesmiddel: Surabgene Lomparvovec

Solution Injection

Geneesmiddel: Topical Steroid

Topical Drops
Experimenteel: Phase 2b: Surabgene Lomparvovec + Steroid-Regimen B

Participants will receive a single SCS injection dose of surabgene lomparvovec (sura-vec) + steroid-Regimen B.
Geneesmiddel: Surabgene Lomparvovec

Solution Injection

Geneesmiddel: Topical Steroid

Topical Drops
Placebo-vergelijker: Phase 2b: Sham + Artificial Tears -Regimen A

Participants will receive a single injection of sham+ artificial tears -Regimen A.
Geneesmiddel: Sham

needleless injection without fluid

Geneesmiddel: Artificial Tears

Topical Drops
Placebo-vergelijker: Phase 2b: Sham + Artificial Tears -Regimen B

Participants will receive a single injection of Sham+ artificial tears -Regimen B.
Geneesmiddel: Sham

needleless injection without fluid

Geneesmiddel: Artificial Tears

Topical Drops
Experimenteel: Phase 3: Surabgene Lomparvovec + Steroid

Participants will receive a single SCS injection dose of Surabgene Lomparvovec + Steroid
Geneesmiddel: Surabgene Lomparvovec

Solution Injection

Geneesmiddel: Topical Steroid

Topical Drops
Placebo-vergelijker: Phase 3: Sham + Artificial Tears

Participants will receive a single injection of Sham + artificial tears.
Geneesmiddel: Sham

needleless injection without fluid

Geneesmiddel: Artificial Tears

Topical Drops
Experimenteel: Bilateral: B1-Surabgene Lomparvovec + Steroid

Participants will receive a single SCS injection dose of Surabgene Lomparvovec + Steroid eye drops in each eye.
Geneesmiddel: Surabgene Lomparvovec

Solution Injection

Geneesmiddel: Topical Steroid

Topical Drops
Experimenteel: Bilateral: B2-Surabgene Lomparvovec + Steroid

Participants will receive a single SCS injection dose of Surabgene Lomparvovec +Steroid eye drops in each eye.
Geneesmiddel: Surabgene Lomparvovec

Solution Injection

Geneesmiddel: Topical Steroid

Topical Drops

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 2B: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 3: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Bilateral Portion: Bilateral portion: Number of participants experiencing ocular Adverse Events (AEs), Serious Adverse Events (SAEs), or any Adverse Events of Special Interest (AESIs)
Tijdsspanne: Up to Approximately Week 104

Safety of bilateral administration with sura-vec will be assessed with Ocular AEs, SAEs, and AESIs. An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Up to Approximately Week 104
Bilateral Portion: Participants Who Experience Intraocular Inflammation
Tijdsspanne: Up to Approximately Week 104

Percentage of participants who experience intraocular inflammation.
Up to Approximately Week 104
Bilateral Portion: Participants Who Experience Scleral Inflammation Including Episcleritis
Tijdsspanne: Up to Approximately Week 104

Percentage of participants who experience scleral inflammation including episcleritis.
Up to Approximately Week 104

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 2B: Percentage of Participants Who Develop a Vision-Threatening Event (VTE) due to Diabetic Retinopathy (DR)
Tijdsspanne: Up to Approximately Week 52

Participants will be assessed for the development of VTEs
Up to Approximately Week 52
Phase 2B: Percentage of Participants Who Develop a Vision-Threatening Event (VTE) due to Diabetic Retinopathy (DR)
Tijdsspanne: Up to Approximately Week 104

Participants will be assessed for the development of VTEs
Up to Approximately Week 104
Phase 2B: Percentage of Participants Who Experience Progression to Proliferative Diabetic Retinopathy (PDR) or Anterior Segment Neovascularization (ASNV) in the Study Eye
Tijdsspanne: Up to Approximately Week 52

Participants will be assessed for the progression to PDR or ASNV.
Up to Approximately Week 52
Phase 2B: Percentage of Participants Who Experience Progression to Proliferative Diabetic Retinopathy (PDR) or Anterior Segment Neovascularization (ASNV) in the Study Eye
Tijdsspanne: Up to Approximately Week 104

Participants will be assessed for the progression to PDR or ASNV.
Up to Approximately Week 104
Phase 2B: Percentage of Participants Who Develop Center Involved-Diabetic Macular Edema (CI-DME) in the Study Eye
Tijdsspanne: Up to Approximately Week 52

Participants will be assessed for the development of CI-DME.
Up to Approximately Week 52
Phase 2B: Percentage of Participants Who Develop Center Involved-Diabetic Macular Edema (CI-DME) in the Study Eye
Tijdsspanne: Up to Approximately Week 104

Participants will be assessed for the development of CI-DME.
Up to Approximately Week 104
Phase 2B: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 2B: Participants Who Develop Treatment-Emergent Ocular Inflammation in the Study Eye.
Tijdsspanne: Up to approximately Week 14

Percentage of participants who develop treatment-emergent ocular inflammation.
Up to approximately Week 14
Phase 2B: Participants Who Develop Treatment-Emergent Ocular Inflammation in the Study Eye.
Tijdsspanne: Up to approximately Week 24

Percentage of participants who develop treatment-emergent ocular inflammation.
Up to approximately Week 24
Phase 2B: Participants Who Develop Treatment-Emergent Ocular Inflammation in the Study Eye.
Tijdsspanne: Up to approximately Week 38

Percentage of participants who develop treatment-emergent ocular inflammation.
Up to approximately Week 38
Phase 2B: Participants Who Develop Treatment-Emergent Ocular Inflammation in the Study Eye.
Tijdsspanne: Up to approximately Week 52

Percentage of participants who develop treatment-emergent ocular inflammation.
Up to approximately Week 52
Phase 2B: Percentage of Participants Achieving>= 2-Step Worsening from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 2B: Percentage of Participants Achieving >= 2-Step Worsening from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 2B: Percentage of Participants With No Change from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 2B: Percentage of participants With No Change from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 2B: Percentage of Participants Achieving >= 2-Step or >= 3-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye.
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 2B: Percentage of Participants Achieving >= 2-Step or >= 3-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye.
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 2B: Percentage of Participants Achieving >= 3-Step Worsening from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 2B: Percentage of Participants Achieving >= 3-Step Worsening from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 2B: Participants With Change from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 2B: Percentage of Participants With Change from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 2B: Participants Who Develop Treatment-Emergent Ocular Inflammation in the Study Eye, Comparing 2 Topical Corticosteroid Regimens for Ocular Inflammation Prophylaxis
Tijdsspanne: Up to approximately Week 14

Percentage of participants who develop treatment-emergent ocular inflammation, comparing 2 topical corticosteroid regimens for ocular inflammation prophylaxis.
Up to approximately Week 14
Phase 2B: Participants Who Develop Treatment-Emergent Ocular Inflammation in the Study Eye, Comparing 2 Topical Corticosteroid Regimens for Ocular Inflammation Prophylaxis
Tijdsspanne: Up to approximately Week 24

Percentage of participants who develop treatment-emergent ocular inflammation, comparing 2 topical corticosteroid regimens for ocular inflammation prophylaxis.
Up to approximately Week 24
Phase 2B: Participants Who Develop Treatment-Emergent Ocular Inflammation in the Study Eye, Comparing 2 Topical Corticosteroid Regimens for Ocular Inflammation Prophylaxis
Tijdsspanne: Up to approximately Week 38

Percentage of participants who develop treatment-emergent ocular inflammation, comparing 2 topical corticosteroid regimens for ocular inflammation prophylaxis.
Up to approximately Week 38
Phase 2B: Participants Who Develop Treatment-Emergent Ocular Inflammation in the Study Eye, Comparing 2 Topical Corticosteroid Regimens for Ocular Inflammation Prophylaxis
Tijdsspanne: Up to approximately Week 52

Percentage of participants who develop treatment-emergent ocular inflammation, comparing 2 topical corticosteroid regimens for ocular inflammation prophylaxis.
Up to approximately Week 52
Phase 2B: Participants Who Receive Treatments for Diabetic Retinopathy (DR) Complications in the Study Eye
Tijdsspanne: Up to Approximately Week 52

Percentage of participants who receive treatments for DR complications in the study eye.
Up to Approximately Week 52
Phase 2B: Participants Who Receive Treatments for Diabetic Retinopathy (DR) Complications in the Study Eye
Tijdsspanne: Up to Approximately Week 104

Percentage of participants who receive treatments for DR complications in the study eye.
Up to Approximately Week 104
Phase 3 (key secondary): Percentage of Participants who develop a Vision-Threatening Event (VTE) due to Diabetic Retinopathy (DR)
Tijdsspanne: Up to Approximately Week 52

Participants will be assessed for the development of VTEs
Up to Approximately Week 52
Phase 3 (key secondary): Percentage of Participants who develop a Vision-Threatening Event (VTE) due to Diabetic Retinopathy (DR)
Tijdsspanne: Up to Approximately Week 104

Participants will be assessed for the development of VTEs
Up to Approximately Week 104
Phase 3 (key secondary): Percentage of Participants Who Experience Progression to Proliferative Diabetic Retinopathy (PDR) or Anterior Segment Neovascularization (ASNV) in the Study Eye
Tijdsspanne: Up to Approximately Week 52

Participants will be assessed for the progression to PDR or ASNV.
Up to Approximately Week 52
Phase 3 (key secondary): Percentage of Participants Who Experience Progression to Proliferative Diabetic Retinopathy (PDR) or Anterior Segment Neovascularization (ASNV) in the Study Eye
Tijdsspanne: Up to Approximately Week104

Participants will be assessed for the progression to PDR or ASNV.
Up to Approximately Week104
Phase 3 (key secondary): Percentage of Participants Who Develop Center Involved-Diabetic Macular Edema (CI-DME) in the Study Eye
Tijdsspanne: Up to Approximately Week 52

Participants will be assessed for the development of CI-DME.
Up to Approximately Week 52
Phase 3 (key secondary): Percentage of Participants Who Develop Center Involved-Diabetic Macular Edema (CI-DME) in the Study Eye
Tijdsspanne: Up to Approximately Week 104

Participants will be assessed for the development of CI-DME.
Up to Approximately Week 104
Phase 3 (key secondary):Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 3: Percentage of Participants Achieving >= 2-Step Worsening from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 3: Percentage of Participants With No change from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 3: Percentage of Participants With Change from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 3: Percentage of Participants Achieving >= 2-Step or >= 3-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye.
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 3: Percentage of Participants Achieving >= 2-Step or >= 3-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye.
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 3: Percentage of Participants Achieving >= 3-Step Worsening from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 52

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 52
Phase 3: Percentage of Participants Achieving >= 3-Step Worsening from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye
Tijdsspanne: At Week 104

The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
At Week 104
Phase 3: Percentage of Participants Who Receive Treatments for Diabetic Retinopathy (DR) Complications in the Study Eye
Tijdsspanne: Up to approximately Week 52

Percentage of participants who receive treatments for DR complications in the study eye.
Up to approximately Week 52
Phase 3: Percentage of Participants Who Receive Treatments for Diabetic Retinopathy (DR) Complications in the Study Eye
Tijdsspanne: Up to approximately Week 104

Percentage of participants who receive treatments for DR complications in the study eye.
Up to approximately Week 104
Bilateral Portion: Percentage of Participants Experiencing Nonocular Adverse Events (AE)s
Tijdsspanne: Up to Approximately Week 104

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Up to Approximately Week 104
Bilateral Portion: Percentage of Participants Experiencing Nonocular Serious Adverse Events (SAE)s
Tijdsspanne: Up to Approximately Week 104

An SAE is defined as any AE, whether or not associated with study treatment that meets any of the following criteria: death of a participant, hospitalization or prolonged hospitalization, congenital anomaly, persistent or significant disability/incapacity, and important medical event requiring medical or surgical intervention to prevent serious outcome.
Up to Approximately Week 104
Bilateral Portion: Percentage of Participants With Vector Shedding in Urine
Tijdsspanne: Up to Approximately Week 12

Vector shedding in urine is defined as measurement of vector Deoxyribonucleic Acid (DNA) concentrations in urine.
Up to Approximately Week 12
Bilateral Portion: Percentage of Participants With Vector Shedding in Tears
Tijdsspanne: Up to Approximately Week 12

Vector shedding in tears is defined as measurement of vector DNA concentrations in tears.
Up to Approximately Week 12
Bilateral Portion: Percentage of Participants With Vector DNA Concentrations in Serum
Tijdsspanne: Up to Approximately Week 104

Vector shedding in urine is defined as measurement of vector DNA concentrations in serum.
Up to Approximately Week 104
Bilateral Portion: Percentage of Participants With Change from Baseline in Diabetic Retinopathy Severity Scale (DRSS) Level
Tijdsspanne: Up to Approximately Week 104

Change from baseline in DRSS level is defined as 0-step (no change), a ≥ 1-step, a ≥ 2-step, or a ≥ 3-step change.
Up to Approximately Week 104
Bilateral Portion: Maintenance of Visual Acuity From Baseline
Tijdsspanne: Up to Approximately Week 104

Maintenance of visual acuity is defined as not losing 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline.
Up to Approximately Week 104
Bilateral portion: Change from baseline in serum anti-sura-vec Transgene product (TP) antibodies
Tijdsspanne: Up to Approximately Week 104

Change from baseline in serum anti-sura-vec antibodies
Up to Approximately Week 104
Bilateral Portion: Change from Baseline in Central Retinal Thickness (CRT) on Spectral Domain-Optical Coherence Tomography (SD-OCT)
Tijdsspanne: Up to Approximately Week 104

Change from baseline in CRT on SD-OCT.
Up to Approximately Week 104
Bilateral Portion: Change from Baseline in Aqueous Humor Surabgene Lomparvovec (Sura-vec) Transgene product (TP) Concentration
Tijdsspanne: Up to Approximately Week 104

Change from baseline in aqueous humor sura-vec TP concentration.
Up to Approximately Week 104
Bilateral Portion: Change from Baseline in Serum Sura-vec Transgene product (TP) concentration
Tijdsspanne: Up to Approximately Week 104

Change from baseline in serum sura-vec TP concentration.
Up to Approximately Week 104
Bilateral Portion: Change from Baseline in Anti- Associated Virus Serotype 8 (AAV8) Transgene product (TP) antibodies
Tijdsspanne: Up to Approximately Week 104

Change from baseline in serum anti-AAV8 TP antibodies.
Up to Approximately Week 104
Bilateral Portion: Percentage of Participants who develop a Vision-Threatening Event (VTE) due to Diabetic Retinopathy (DR)
Tijdsspanne: Up to Approximately Week 104

Participants will be assessed for the development of VTEs
Up to Approximately Week 104
Bilateral Portion: Change from Baseline in Enzyme-linked ImmunoSpot (ELISpot to capsid or transgene)
Tijdsspanne: Up to Approximately Week 104

Change from baseline in ELISpot comparing (whole blood) to capsid or transgene.
Up to Approximately Week 104

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

AbbVie

Onderzoekers

  • Studie directeur: ABBVIE INC., AbbVie

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 juni 2026

Primaire voltooiing (Geschat)

1 juni 2028

Studie voltooiing (Geschat)

1 januari 2036

Studieregistratiedata

Eerst ingediend

24 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 mei 2026

Eerst geplaatst (Werkelijk)

18 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

27 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • M23-415

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-tijdsbestek voor delen

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

IPD-toegangscriteria voor delen

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren